195 related articles for article (PubMed ID: 33051943)
1. Relationship between sleep efficacy endpoints and measures of functional status and health-related quality of life in participants with narcolepsy or obstructive sleep apnea treated for excessive daytime sleepiness.
Weaver TE; Mathias SD; Crosby RD; Bron M; Bujanover S; Menno D; Villa KF; Drake C
J Sleep Res; 2021 Jun; 30(3):e13210. PubMed ID: 33051943
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
Weaver TE; Pepin JL; Schwab R; Shapiro C; Hedner J; Ahmed M; Foldvary-Schaefer N; Strollo PJ; Mayer G; Sarmiento K; Baladi M; Bron M; Chandler P; Lee L; Malhotra A
J Clin Sleep Med; 2021 Oct; 17(10):1995-2007. PubMed ID: 34606437
[TBL] [Abstract][Full Text] [Related]
3. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
Malhotra A; Shapiro C; Pepin JL; Hedner J; Ahmed M; Foldvary-Schaefer N; Strollo PJ; Mayer G; Sarmiento K; Baladi M; Chandler P; Lee L; Schwab R
Sleep; 2020 Feb; 43(2):. PubMed ID: 31691827
[TBL] [Abstract][Full Text] [Related]
4. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
Emsellem HA; Thorpy MJ; Lammers GJ; Shapiro CM; Mayer G; Plazzi G; Chen D; Carter LP; Villa KF; Lee L; Menno D; Black J; Dauvilliers Y
Sleep Med; 2020 Mar; 67():128-136. PubMed ID: 31926465
[TBL] [Abstract][Full Text] [Related]
5. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea.
Rosenberg R; Baladi M; Bron M
J Clin Sleep Med; 2021 Apr; 17(4):711-717. PubMed ID: 33226332
[TBL] [Abstract][Full Text] [Related]
6. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
Ronnebaum S; Bron M; Patel D; Menno D; Bujanover S; Kratochvil D; Lucas E; Stepnowsky C
J Clin Sleep Med; 2021 Dec; 17(12):2543-2555. PubMed ID: 34402784
[TBL] [Abstract][Full Text] [Related]
7. Test-retest reliability of the Epworth Sleepiness Scale in clinical trial settings.
Rosenberg R; Babson K; Menno D; Morris S; Baladi M; Hyman D; Black J
J Sleep Res; 2022 Apr; 31(2):e13476. PubMed ID: 34545626
[TBL] [Abstract][Full Text] [Related]
8. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.
Schweitzer PK; Rosenberg R; Zammit GK; Gotfried M; Chen D; Carter LP; Wang H; Lu Y; Black J; Malhotra A; Strohl KP;
Am J Respir Crit Care Med; 2019 Jun; 199(11):1421-1431. PubMed ID: 30521757
[No Abstract] [Full Text] [Related]
9. Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.
Weaver TE; Drake CL; Benes H; Stern T; Maynard J; Thein SG; Andry JM; Hudson JD; Chen D; Carter LP; Bron M; Lee L; Black J; Bogan RK
Ann Am Thorac Soc; 2020 Aug; 17(8):998-1007. PubMed ID: 32353246
[No Abstract] [Full Text] [Related]
10. Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea.
Weaver TE; Menno DM; Bron M; Crosby RD; Morris S; Mathias SD
Sleep Breath; 2021 Sep; 25(3):1707-1715. PubMed ID: 33394323
[TBL] [Abstract][Full Text] [Related]
11. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.
Krystal AD; Benca RM; Rosenberg R; Schweitzer PK; Malhotra A; Babson K; Lee L; Bujanover S; Strohl KP
J Psychiatr Res; 2022 Nov; 155():202-210. PubMed ID: 36070638
[TBL] [Abstract][Full Text] [Related]
12. The Perception and Attention Functions test battery as a measure of neurocognitive impairment in patients with suspected central disorders of hypersomnolence.
Ramm M; Jafarpour A; Boentert M; Lojewsky N; Young P; Heidbreder A
J Sleep Res; 2018 Apr; 27(2):273-280. PubMed ID: 28771870
[TBL] [Abstract][Full Text] [Related]
13. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
Rosenberg R; Thorpy MJ; Dauvilliers Y; Schweitzer PK; Zammit G; Gotfried M; Bujanover S; Scheckner B; Malhotra A
J Clin Sleep Med; 2022 Jan; 18(1):235-244. PubMed ID: 34283019
[TBL] [Abstract][Full Text] [Related]
14. Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial.
Dauvilliers Y; Verbraecken J; Partinen M; Hedner J; Saaresranta T; Georgiev O; Tiholov R; Lecomte I; Tamisier R; Lévy P; Scart-Gres C; Lecomte JM; Schwartz JC; Pépin JL;
Am J Respir Crit Care Med; 2020 May; 201(9):1135-1145. PubMed ID: 31917607
[No Abstract] [Full Text] [Related]
15. Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
Black J; Houghton WC
Sleep; 2006 Jul; 29(7):939-46. PubMed ID: 16895262
[TBL] [Abstract][Full Text] [Related]
16. Solriamfetol for the Management of Excessive Daytime Sleepiness.
Cuomo MC; Sheehan AH; Jordan JK
J Pharm Pract; 2022 Dec; 35(6):963-970. PubMed ID: 33882756
[TBL] [Abstract][Full Text] [Related]
17. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
Dauvilliers Y; Shapiro C; Mayer G; Lammers GJ; Emsellem H; Plazzi G; Chen D; Carter LP; Lee L; Black J; Thorpy MJ
CNS Drugs; 2020 Jul; 34(7):773-784. PubMed ID: 32588401
[TBL] [Abstract][Full Text] [Related]
18. Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: A meta-analysis from randomized controlled trials.
Wang J; Li X; Yang S; Wang T; Xu Z; Xu J; Gao H; Chen G
Pharmacol Res; 2021 May; 167():105522. PubMed ID: 33667687
[TBL] [Abstract][Full Text] [Related]
19. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives.
Abad VC
Nat Sci Sleep; 2021; 13():75-91. PubMed ID: 33531850
[TBL] [Abstract][Full Text] [Related]
20. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.
Schweitzer PK; Mayer G; Rosenberg R; Malhotra A; Zammit GK; Gotfried M; Chandler P; Baladi M; Strohl KP
Chest; 2021 Jul; 160(1):307-318. PubMed ID: 33631141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
